News

2020

Confo Therapeutics expands Board with appointment of Rob Scott as Independent Director

10 June 2020

Mainstay Medical announces reimbursement approval for ReActiv8 in Australia

8 June 2020

Confo Therapeutics appoints Paolo Vicini as Chief Development Officer

3 June 2020

iSTAR Medical announces outstanding results with MIGS implant

29 April 2020

Nexstim reports promising clinical outcomes of first 55 patients completing SmartFocus® rTMS treatment of Major Depressive Disorder

17 April 2020

Sequana Medical announces first-in-human data of Direct Sodium Removal (DSR) therapy published in Circulation

10 January 2020

Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients

7 January 2020

2019

Confo Therapeutics reports grant of two key patents for ConfoBodies™

2 December 2019

Sequana Medical announces first patient enrolled in North American alfapump® pivotal study (POSEIDON)

25 September 2019

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

23 September 2019

iSTAR Medical announces € 40 million Series C financing

5 September 2019

Mainstay Medical announces completion of financing transactions

30 July 2019

• 1
• 2
• 3
• 4
• 5
• 6